A Phase 3, multicentre, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL 112 in subjects with Acute Coronary Syndrome protocol #: CSL 112_3001 (the ApoA-1 Event ReducinG in Ischaemic Syndromes II (AEGIS-II) Study.
- Shaw, James (Primary Chief Investigator (PCI))
Project: Research